Steven R. Alves

Steven R. Alves

Auto-generated profile, based on publicly available information

Steven R. Alves

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, New York, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
YCYuxin Cen
Yuxin Cen
SASteven R. Alves
Steven R. Alves
DSDongyan Song
Dongyan Song
JPJonathan Preall
Jonathan Preall
LALinda Van Aelst
Linda Van Aelst
NTNicholas K. Tonks
Nicholas K. Tonks
Amyloid-β (Aβ) accumulation is a hallmark of Alzheimer’s disease (AD). Emerging evidence suggests that impaired microglial Aβ phagocytosis is a key feature in AD, highlighting the therapeutic potential of enhancing this innate immune function. Here, we demonstrate that genetic deletion or pharmacological inhibition of protein tyrosine phosphatase 1B (PTP1B) ameliorated memory deficits and reduced Aβ burden in APP/PS1 mice. Moreover, we show that PTP1B was highly expressed in microglia, and its deficiency promoted a transcriptional shift toward immune activation and phagocytosis. Consistently, PTP1B deletion in microglia enhanced phagocytosis and metabolic fitness, supported by increased AKT-mTOR signaling, a pathway essential for meeting the energy demands of activation. Mechanistically, we identified spleen tyrosine kinase (SYK), a key regulator of microglial phagocytosis, as a direct substrate of PTP1B. Inhibition of SYK showed that PTP1B modulates microglial activation in a SYK-dependent manner. These findings established PTP1B as a critical modulator of microglial activation and a potential therapeutic target for AD.

2 February 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YCYuxin Cen
Yuxin Cen
SASteven R. Alves
Steven R. Alves
DSDongyan Song
Dongyan Song
CFChristy Felice
Christy Felice
JPJonathan B. Preall
Jonathan B. Preall
NTNicholas K. Tonks
Nicholas K. Tonks
Amyloid β (Aβ) accumulation is a hallmark of Alzheimer’s disease (AD). Emerging evidence suggests that impaired microglial Aβ phagocytosis is a key feature in AD, highlighting the therapeutic potential of enhancing this innate immune function. Here, we demonstrate that genetic deletion or pharmacological inhibition of protein tyrosine phosphatase 1B (PTP1B) ameliorated memory deficits and reduced Aβ burden in APP/PS1 mice. Moreover, we show that PTP1B was highly expressed in microglia, and its deficiency promoted a transcriptional shift toward immune activation and phagocytosis. Consistently, PTP1B deletion in microglia enhanced phagocytosis and energy metabolism, supported by increased AKT-mTOR signaling, a pathway essential for meeting the energy demands of activation. Mechanistically, we identified spleen tyrosine kinase (SYK), a key regulator of microglial phagocytosis, as a direct substrate of PTP1B. Inhibition of SYK showed that PTP1B modulates microglial activation in a SYK-dependent manner. These findings established PTP1B as a critical modulator of microglial activation and a potential therapeutic target for AD.

1 May 2023 in Proteomics
Verified
Journal Article
Open access
MFMaria José Ferreira
Maria José Ferreira
Tânia Cristina Soares MartinsTânia Cristina Soares Martins
Tânia Cristina Soares Martins
SASteven R. Alves
Steven R. Alves
IRIlka Martins Rosa
Ilka Martins Rosa
JVJonathan Vogelgsang
Jonathan Vogelgsang
AHAna Gabriela Henriques
Ana Gabriela Henriques
Aging is the main risk factor for the appearance of age‐related neurodegenerative diseases, including Alzheimer's disease (AD). AD is the most common form of dementia, characterized by the presence of senile plaques (SPs) and neurofibrillary tangles (NFTs), the main histopathological hallmarks in AD brains. The core of these deposits are predominantly amyloid fibrils in SPs and hyperphosphorylated Tau protein in NFTs, but other molecular components can be found associated with these pathological lesions. Herein, an extensive literature review was carried out to obtain the SPs and NFTs proteomes, followed by a bioinformatic analysis and further putative biomarker validation. For SPs, 857 proteins were recovered, and, for NFTs, 627 proteins of which 375 occur in both groups and represent the common proteome. Gene Ontology (GO) enrichment analysis permitted the identification of biological processes and the molecular functions most associated with these lesions. Analysis of the SPs and NFTs common proteins unraveled pathways and molecular targets linking both histopathological events. Further, validation of a putative phosphotarget arising from the in silico analysis was performed in serum‐derived extracellular vesicles from AD patients. This bioinformatic approach contributed to the identification of putative molecular targets, valuable for AD diagnostic or therapeutic intervention.

20 May 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
IZImanol Zubiete-Franco
Imanol Zubiete-Franco
QHQingting Hu
Qingting Hu
SASteven R. Alves
Steven R. Alves
RURaditya Utama
Raditya Utama
NTNicholas K. Tonks
Nicholas K. Tonks
CDKL5-deficiency disorder or CDD, which results in intellectual disability, speech, and motor deficits, and seizures that can start as early as 6 weeks after birth, is caused by de novo mutations in the CDKL5 gene. In early 2022, the FDA approved ganaxolone (Commercial name: Ztalmy) for the treatment of seizures in CDD patients 2 years and older. Ganaxolone has been reported to act as a GABAA receptor agonist that helps reduce neuronal excitability; however, based on its chemical structure, we hypothesized that ganaxolone may also act as a PTP1B inhibitor. We observed that ganaxalone was able to inhibit PTP1B activity both in an in vitro assay of enzyme activity and in different cell models, with similar potency to known inhibitors of PTP1B, including MSI-1436, which has a similar chemical structure. Additionally, inhibition of PTP1B in differentiating SH-SY5Y cells increased TRKB/BDNF signaling. This effect was prominent in CDKL5-KO cells, which have increased PTP1B expression. In these cells, inhibition of PTP1B not only brought BDNF signaling to levels similar to those of WT cells but also restored cellular morphology. Our results suggest that, like in Rett syndrome, targeting PTP1B may be a beneficial therapeutic strategy for CDD.